Mark M Davis

This inventor holds 24 USPTO granted patents and 15 published patent applications and 2 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Leland Stanford Junior University, Edifice Health, Inc., Howard Hughes Medical Institute. Active years: 1991-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark M Davis. Retrieved from https://idiyas.com/inventor/mark-m-davis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 24 (Patent Applications = 15)

% Patents Active = 70.8

EPO Patents = 2 (Patent Applications = 14)

Average Co-Inventor Count = 3.1

ph-index = 6

Forward Citations = 177(Granted Patents)

Location History:

Mountain View, CA (US) (1991 - 2001)
Atherton, CA (US) (1997 - 2024)

Company Filing History:

20 out of 5,519

Leland Stanford Junior University

Howard Hughes Medical Institute

patents

4. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1991-2026

Loading Chart...

Areas of Expertise:

Toll-Like Receptor Agonist

Nanoparticle Vaccine

Cancer Immunotherapy

T Cell Modulation

HLA Loci

Single Cell Analysis

Immunostimulatory Compounds

Hydrogels

MHC-Antigen Arrays

Immune Impairment

Multiplex Measurements

Regulatory T Cells

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12691173 - Toll-like receptor agonist-nanoparticle vaccine adjuvant (2026-07-28),

2. 12678516 - Immunostimulatory toll-like receptor agonist-nanoparticle for cancer immunotherapy (2026-07-14),

3. 12636317 - MANIPULATION AND USE OF ANTIGEN-SPECIFIC REGULATORY T CELLS (2026-05-26),

4. 12517135 - Method for measuring systemic chronic inflammaging (2026-01-06),

5. 12440544 - Cross-reactive epitope for multiple sclerosis (2025-10-14),

6. 12433959 - Injectable hydrogels for controlled release of immunomodulatory compounds (2025-10-07),

7. 12377396 - Systems and methods for multiplexed measurements in single and ensemble cells (2025-08-05),

8. 11925693 - Polymeric nanoparticles for enhanced cancer immunotherapy (2024-03-12),

9. 10202640 - Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing (2019-02-12),

10. 10119959 - Method of assaying an individual for immune impairment (2018-11-06),

11. 9920370 - Haplotying of HLA loci with ultra-deep shotgun sequencing (2018-03-20),

12. 9598695 - Modulation of T cell signaling threshold and T cell sensitivity to antigens (2017-03-21),

13. 9562269 - Haplotying of HLA loci with ultra-deep shotgun sequencing (2017-02-07),

14. 9527912 - Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade (2016-12-27),

15. 9364522 - Modulation of T cell signaling threshold and T cell sensitivity to antigens (2016-06-14),

Title: The Inventor Mark M Davis: Pioneering Innovations in Atherton, CA

Introduction: Mark M Davis is a distinguished inventor based in Atherton, CA, known for his groundbreaking contributions to various fields.

Latest Patents: Mark M Davis holds several patents in the areas of technology and healthcare, showcasing his versatility and ingenuity.

Career Highlights: With a career spanning over two decades, Mark M Davis has consistently pushed the boundaries of innovation, leading to significant advancements in his respective industries.

Collaborations: Throughout his career, Mark M Davis has collaborated with top researchers, scientists, and engineers, fostering a culture of innovation and excellence.

Conclusion: Mark M Davis stands as a testament to the power of creativity and perseverance in the world of inventions, leaving a lasting impact on the innovation landscape.

Profile summary based on public USPTO records.